Xin Lang Cai Jing·2025-07-18 07:14Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 0.56% on July 18, with a trading volume of 2.25 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 17, 2024, the fund's latest share count was 2.025 billion, with a total size of 3.63 billion yuan, reflecting an increase of 412.28% in shares and 860.92% in size since December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 79.25% during the management period [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's trading liquidity is strong, with a cumulative trading amount of 40.368 billion yuan over the last 20 trading days, averaging 2.018 billion yuan per day [1][2]